Last reviewed · How we verify
NCT06300762
RCT Exudate Management Cutimed Sorbion Product Range
NA trial testing Superabsorbent dressing application in Venous Leg Ulcer in 152 participants. Currently enrolling.
30 November 2025
Quick facts
| Lead sponsor | BSN Medical GmbH |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 152 |
| Start date | 10 August 2024 |
| Primary completion | 30 November 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 3 locations across United Kingdom, Germany |
Drugs / interventions tested
- Superabsorbent dressing application
Conditions studied
- Venous Leg Ulcer — all drugs for Venous Leg Ulcer →
Sponsor
BSN Medical GmbH
Who can join
18 and older, any sex, with Venous Leg Ulcer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The fluid handling capacity of superabsorbent dressings varies depending on the design and construction. The use of effective advanced wound dressings is a promising strategy to achieve adequate absorption of wound exudate and malodour promoting wound healing. The aim of the current study is to determine whether there is a difference in the clinical performance of exudate absorption with two commonly used CE-marked superabsorbent dressings when used on VLUs in routine wound care. As primary objective the dressing´s absorption performance and its ability to prevent skin maceration and leakage of the wound dressing will be investigated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06300762
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Venous Leg Ulcer
Currently open trials in the same condition.
- NCT07255937 — PMCF Study of Debridement Pad · NA · recruiting
- NCT07046767 — CAMP RWE Trial: Amnion Grafts for Healing Hard-to-Heal Ulcers in RW Populations · NA · recruiting
- NCT07211243 — Suprasorb®X+PHMB Pro vs Suprasorb®X+PHMB in Treatment of Infected Venous Leg Ulcers · NA · recruiting
- NCT07061613 — Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Venous Leg Ulcers · NA · recruiting
- NCT06544564 — Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population · NA · recruiting
Other BSN Medical GmbH trials
Trials by the same sponsor.
- NCT05347927 — Observational Study to Evaluate the Influence of Undercast Material Types on Skin Microbiome · completed
- NCT05148390 — Study to Examine Clinical Performance and Safety of Cutimed® Gelling Fiber in Routine Clinical Practice · completed
- NCT04775316 — Prospective, International, Multicenter, Observational Study to Evaluate the Clinical Performance and Safety of a Silico · terminated
- NCT04901962 — Study to Evaluate Made-to-measure Compression Garments · NA · completed
- NCT04731753 — PMCF Study to Examine the Debridement Pad Cutimed DebriClean · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06300762 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BSN Medical GmbH
- Last refreshed: 31 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06300762.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing